Latest Period
Q2 2026
Security Snapshot
Soleno Therapeutics, Inc. - Common Stock (SLNO) Institutional Ownership
CUSIP: 834203309
13F Institutional Holders and Ownership History from Q3 2022 to Q2 2026
Institutions Reporting
0
Shares (Excl. Options)
0
Price
$53.01
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- SLNO
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 0
- Total 13F value
- $0
- Share change
- -54,615,873
- Value change
- -$1,826,032,539
- Number of holders
- 0
- Shares outstanding
- 51,293,400
- SEC-reported price per share
- $53.01
- Insider filing price
- $53.01
Latest holder snapshot
4 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- SLNO - Soleno Therapeutics, Inc. - Common Stock is tracked under CUSIP 834203309.
- 0 institutions reported positions in Q2 2026.
- 10 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 224 to 0 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $2,080,448,333 to $0.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 0 institutions filings for Q2 2026.
Security key
834203309
Latest holder period
Q2 2026
13F holders
0
13D/G owners
10
CIK / CUSIP context first
Open Q2 2026 holders
SLNO full holder history
SOLENO THERAPEUTICS INC SEC filings
SOLENO THERAPEUTICS INC company facts
SOLENO THERAPEUTICS INC insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 834203309:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
10
Security
SLNO
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 6.9% | +23% | $118,629,904 | +$26,016,415 | 3,543,296 | +28% | BlackRock, Inc. | 31 Mar 2026 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 6.4% | $204,422,873 | 2,775,976 | Adage Capital Management, L.P. | 31 Dec 2024 | |||
| STATE STREET CORP | 5.2% | $140,768,913 | 2,680,802 | STATE STREET CORPORATION | 31 Mar 2026 | |||
| Avoro Capital Advisors LLC | 4.4% | -19% | $120,773,000 | -$31,506,000 | 2,300,000 | -21% | Avoro Capital Advisors LLC | 31 Mar 2026 |
| Vivo Opportunity Fund Holdings, L.P. | 4.2% | -46% | $152,178,416 | -$115,402,258 | 2,251,160 | -43% | Vivo Opportunity Fund Holdings, L.P. | 30 Sep 2025 |
| Adage Capital Management, L.P. | 2.6% | -64% | $94,746,538 | -$146,988,629 | 1,401,576 | -61% | Adage Capital Management, L.P. | 30 Sep 2025 |
| JANUS HENDERSON GROUP PLC | 2.3% | -85% | $63,290,461 | -$313,644,908 | 1,205,303 | -83% | JANUS HENDERSON GROUP PLC | 30 Apr 2026 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2% | -70% | $53,868,329 | -$127,895,561 | 1,025,868 | -70% | T. Rowe Price Associates, Inc. | 31 Mar 2026 |
| Nantahala Capital Management, LLC | 2% | -60% | $86,766,978 | -$140,918,982 | 1,001,350 | -62% | Nantahala Capital Management, LLC | 30 Jun 2025 |
| FMR LLC | 0.4% | -98% | $10,135,145 | -$292,764,044 | 193,014 | -97% | FMR LLC | 30 Apr 2026 |
As of 30 Jun 2026, 0 institutional investors reported holding 0 shares of Soleno Therapeutics, Inc. - Common Stock (SLNO). This represents 0% of the company’s total 51,293,400 outstanding shares.
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
16
Latest
Q2 2026
Rows shown
1-16 of 16
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 0 | $0 | -$1,826,032,539 | $53.01 | 0 |
| 2026 Q1 | 62,216,756 | $2,080,448,333 | -$136,049,933 | $33.48 | 224 |
| 2025 Q4 | 64,916,991 | $3,006,117,784 | -$193,286,405 | $46.30 | 247 |
| 2025 Q3 | 65,165,847 | $4,403,391,909 | +$507,196,048 | $67.60 | 237 |
| 2025 Q2 | 56,749,470 | $4,754,316,405 | +$213,454,357 | $83.78 | 231 |
| 2025 Q1 | 54,568,286 | $3,901,554,193 | +$304,734,926 | $71.45 | 215 |
| 2024 Q4 | 51,039,620 | $2,293,782,533 | +$169,954,638 | $44.95 | 164 |
| 2024 Q3 | 47,119,847 | $2,378,750,710 | +$200,292,187 | $50.49 | 140 |
| 2024 Q2 | 43,315,547 | $1,767,618,917 | +$339,170,617 | $40.80 | 112 |
| 2024 Q1 | 34,986,278 | $1,496,099,214 | +$153,335,358 | $42.80 | 97 |
| 2023 Q4 | 31,409,972 | $1,264,282,488 | +$428,860,586 | $40.25 | 76 |
| 2023 Q3 | 20,301,195 | $598,794,549 | +$451,363,927 | $29.51 | 54 |
| 2023 Q2 | 4,852,710 | $20,757,863 | +$7,837,293 | $4.29 | 22 |
| 2023 Q1 | 3,071,637 | $6,538,076 | +$3,161,387 | $2.14 | 20 |
| 2022 Q4 | 2,785,956 | $5,517,109 | +$81,616 | $1.98 | 22 |
| 2022 Q3 | 2,781,988 | $4,645,586 | +$4,630,000 | $1.67 | 14 |